Literature DB >> 35903540

Neoantigen Presentation and IFNγ Signaling on the Same Tumor-associated Macrophage are Necessary for CD4 T Cell-mediated Antitumor Activity in Mice.

Ainhoa Perez-Diez1, Xiangdong Liu1, Polly Matzinger1.   

Abstract

Tumor Associated Macrophages (TAMs) promote tumor survival, angiogenesis and metastases. Although they express MHC Class II molecules, little is known about their ability to present tumor antigens to tumor infiltrating CD4 T cells, nor what are the consequences of such presentation. To answer these questions, we used a C57/BL10 mouse tumor model where we subcutaneously implant a bladder carcinoma cell line naturally expressing the H-Y male antigen into female mice, making the H-Y antigen a de facto neoantigen. We found that TAMs indeed present tumor antigens to effector CD4 T cells and that such presentation is necessary for tumor rejection. As consequence of this interaction TAMs are re-educated to produce lower amounts of tumor promoting proteins and greater amounts of inflammatory proteins. The re-education process of the TAMs is transcriptionally characterized by an IFN-γ signature, including genes of known anti-viral and anti-bacterial functions. CD4 production of IFN-γ, and not TNF-α or CD40L, is required for the re-education process and tumor rejection. Furthermore, IFN-γ signaling on antigen presenting TAMs and not on bystander TAMs, is necessary for the anti-tumor effect. These data identify critical mechanisms of tumor rejection by CD4 T cells and underscores the importance of effector CD4 T cell-tissue macrophage interactions not only at the tumors site but potentially in other tissues.

Entities:  

Keywords:  Tumor Associated Macrophages; antigen presentation; molecular signature of re-educated macrophages; neoantigen; tumor specific CD4 T cells

Year:  2022        PMID: 35903540      PMCID: PMC9321644          DOI: 10.1158/2767-9764.crc-22-0052

Source DB:  PubMed          Journal:  Cancer Res Commun        ISSN: 2767-9764


  56 in total

Review 1.  The role of CD40 ligand in costimulation and T-cell activation.

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Rev       Date:  1996-10       Impact factor: 12.988

2.  Evolutionary Pressure against MHC Class II Binding Cancer Mutations.

Authors:  Rachel Marty Pyke; Wesley Kurt Thompson; Rany M Salem; Joan Font-Burgada; Maurizio Zanetti; Hannah Carter
Journal:  Cell       Date:  2018-12-13       Impact factor: 41.582

3.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Authors:  Masahisa Jinushi; Shigeki Chiba; Hironori Yoshiyama; Kenkichi Masutomi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Hideo Yagita; Akinori Takaoka; Hideaki Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

4.  Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells.

Authors:  Nicholas Stephen Rennie Sanderson; Mariana Puntel; Kurt M Kroeger; Niyati S Bondale; Mark Swerdlow; Niloufar Iranmanesh; Hideo Yagita; Ahmed Ibrahim; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

5.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

6.  Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Authors:  Kimberly A Shafer-Weaver; Stephanie K Watkins; Michael J Anderson; Lauren J Draper; Anatoli Malyguine; W Gregory Alvord; Norman M Greenberg; Arthur A Hurwitz
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

7.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Authors:  David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

8.  Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.

Authors:  Nikolaos Zacharakis; Harshini Chinnasamy; Mary Black; Hui Xu; Yong-Chen Lu; Zhili Zheng; Anna Pasetto; Michelle Langhan; Thomas Shelton; Todd Prickett; Jared Gartner; Li Jia; Katarzyna Trebska-McGowan; Robert P Somerville; Paul F Robbins; Steven A Rosenberg; Stephanie L Goff; Steven A Feldman
Journal:  Nat Med       Date:  2018-06-04       Impact factor: 53.440

9.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

10.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.

Authors:  Kevin Litchfield; James L Reading; Clare Puttick; Krupa Thakkar; Chris Abbosh; Robert Bentham; Thomas B K Watkins; Rachel Rosenthal; Dhruva Biswas; Andrew Rowan; Emilia Lim; Maise Al Bakir; Virginia Turati; José Afonso Guerra-Assunção; Lucia Conde; Andrew J S Furness; Sunil Kumar Saini; Sine R Hadrup; Javier Herrero; Se-Hoon Lee; Peter Van Loo; Tariq Enver; James Larkin; Matthew D Hellmann; Samra Turajlic; Sergio A Quezada; Nicholas McGranahan; Charles Swanton
Journal:  Cell       Date:  2021-01-27       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.